After the green light of‘Aifa (Italian Medicines Agency) arrived in December, Nuvaxovid, the new Covid vaccine produced by Novavax is arriving in Italy in the first half of February. It is the fifth vaccine authorized in Europe against the coronavirusafter the preparations of Pfizer-BioNTech, Moderna, AstraZeneca and Janssen (Johnson & Johnson).
The new serum, based on recombinant proteins, with which the government hopes it will convince the many skeptics of vector and mRNA-based vaccines, will be reserved only for the first administrations of the over 18s, therefore not as a booster. The recall will be made after 21 days.
Two largest vaccine studies. The first, conducted in Mexico and the United States, found a 90.4% reduction in the number of symptomatic cases of Covid-19 from 7 days after the second dose. The second study, conducted in the UK, also showed a similar reduction in the number of symptomatic cases of Covid-19, with the vaccine’s efficacy at 89.7%. Taken together, the EMA explained, “the results of the two studies show an efficacy of the Nuvaxovid vaccine of about 90%”. “The safety and efficacy of the vaccine – concludes the note – will continue to be monitored as it is used throughout the EU, through the EU pharmacovigilance system and further studies by the company and the European authorities” .
The safety profile – notes the CTS, on the Nuvaxovid vaccine – proved to be positive, with mainly local adverse reactions. In Italy, the first administrations will take place in Lazio in 15 hubs throughout the Region of which seven in the capital.
How does it work
Unlike the new generation vaccines, which are a mRna (Pfizer and Moderna) or a viral vector (J&J and Astrazeneca) which instruct our cell to produce the spike protein and consequently stimulate the body to produce antibodies, the Novavax introduces tiny particles made from a lab-made version of the spike protein, prompting our bodies to respond, and an “adjuvant,” a substance that helps boost immune responses to the vaccine.
When a person is given the vaccine, their immune system will identify the protein particle as foreign and produce natural defenses against it. If the vaccinated person later comes into contact with the Sars-Cov-2 virus, his immune system will recognize the spike protein on the virus and be ready to attack it.
The operation on which Novavax is based is already consolidated and similar to that of numerous other classic vaccines, such as the one already in use against hepatitis B and the papilloma virus.